Synthesis and in vitro antitumor activity of novel diaryl urea derivatives

Chinese Chemical Letters

Volumn 24, Issue 5, 2013, Pages 386-388

  Zhao, Yan Fang ^a   Liu, Zi Jian ^a   Zhai, Xin ^a   Ge, Dan Dan ^a   Huang, Qiang ^a   Gong, Ping ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Antitumor activity in vitro; Diaryl ureas; Synthesis

Indexed keywords

EID: 84877697666     PISSN: 10018417     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cclet.2013.02.004     Document Type: Article

References (7)

1. H.Q. Li, P.C. Lv, T. Yan, and H.L. Zhu Urea derivatives as anticancer agents Anticancer Agents Med. Chem. 10 2009 471 480
2. S. Wilhelm, C. Carter, and M. Lynch Discovery and development of sorafenib: a multikinase inhibitor for treating cancer Nat. Rev. Drug Discov. 5 2006 835 844
3. Y.J. Dai, K. Hartandi, and Z.Q. Ji Discovery of N-(4-(3-amino-1H-indazol- 4-yl)phenyl)-N′-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor J. Med. Chem. 50 2007 1584 1597
4. K. Nakamura, E. Taguchi, and T. Miura KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties Cancer Res. 66 2006 9134 9142
5. S.M. Wilhelm, C. Carter, and L.Y. Tang BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor Cancer Res. 64 2004 7099 7109
6. R.C. Kan, A.T. Farrell, and H. Saber Sorafenib for the treatment of advanced renal cell carcinoma Clin. Cancer Res. 12 2006 7271 7278
7. G.M. Keating, and A. Santoro Sorafenib: a review of its use in advanced hepatocellular carcinoma Drugs 69 2009 223 240